The Use and Importance of Artificial Intelligence in Vaccine Research, Development and Production

Muhammad Yasir Naeem[1], Batuhan Selamoglu[2], Koshanova Gulnazira Danebekovna[3], Mesut Selamoglu[4], Zeliha Selamoglu[5,6,7*]

[1]Department of Agronomy, Animals, Food, Natural Resources and the Environment (DAFNAE), University of Padova, Italy

[2]Mersin University, Institute of Science, Electrical and Electronic Engineering, Mersin, Turkey

[3]Khoja Akhmet Yassawi International Kazakh-Turkish University, Faculty of Sciences, Department of Mathematics, Central Campus, Turkestan, Kazakhstan

[4]Osmaniye Korkut Ata University, Bahce Vocational School, Management and Organization, Osmaniye, Turkey

[5]Department of Medical Biology, Medicine Faculty, Nigde Omer Halisdemir University, Nigde, Turkey

[6]Western Caspian University, Baku, Azerbaijan

[7]Khoja Akhmet Yassawi International Kazakh-Turkish University, Faculty of Sciences, Department of Biology, Central Campus, Turkestan, Kazakhstan

Corresponding Author's Email: zselamoglu@ohu.edu.tr

Abstract

Artificial intelligence (AI) refers to a variety of computing approaches, including machine learning, deep learning, natural language processing, and computer vision. AI has transformed healthcare, with applications ranging from diagnostics to personalised medicine, drug development, and clinical trial optimisation. The advancement of vaccine creation, research, and manufacturing is being significantly impacted by AI. The integration of AI into vaccine research, development, and production has the potential to revolutionize traditional methodologies, significantly accelerating the process of bringing vaccines to market. This review aims to evaluate the role of AI technologies—such as machine learning, deep learning, and natural language processing—in identifying vaccine targets, optimizing formulations, and streamlining manufacturing processes. AI facilitates the analysis of extensive datasets, enabling predictive analytics that enhance the selection of promising vaccine candidates and improve trial outcomes. Furthermore, AI-driven optimization of supply chains enhances vaccine distribution, particularly in low-resource settings, addressing global disparities in access to immunizations. Despite these advancements, challenges remain, including ethical concerns related to data privacy, algorithmic bias, and the integration of AI into existing frameworks. Future directions point toward advancements in AI technologies, including quantum computing, which could further enhance vaccine development efficiency. Collaboration between AI experts and vaccine researchers is crucial for maximizing the potential of AI and ensuring equitable access to vaccines globally. The vaccination distribution may be optimised by AI-powered logistics systems, guaranteeing that doses are given to the appropriate places at the appropriate times. AI can identify the most effective ways to deliver vaccines, minimising delays and saving waste, by analysing data on transportation routes, storage capacity, and cold chain needs. This review highlights the transformative impact of AI on the vaccine development landscape and underscores its importance in responding to emerging infectious diseases and public health crises.

Keywords: Computational biology, machine learning, immune-informatics, biopharmaceuticals, predictive analytics.

1. Introduction

1.1. Context on Vaccine Development

Vaccinations are one of the greatest medical achievements in human history, credited with nearly eradicating fatal diseases like polio and smallpox. Despite this success, vaccine development has historically been a challenging process, requiring substantial time, financial investment, and resources. The development process is typically broken down into several critical phases: exploratory research, preclinical testing, clinical trials, regulatory approval, and mass manufacturing and distribution. Each phase comes with its own set of difficulties. For example, identifying suitable antigens and understanding their immunogenic properties may take years. The inefficiencies of traditional vaccine development have been especially evident during global health crises, such as the 2009 H1N1 influenza pandemic and the 2014–2016 Ebola virus outbreaks, where the creation of vaccines lagged behind the rapid spread of the viruses. While advances in bioinformatics and molecular biology have enhanced the accuracy of pathogen targeting, these fields have not been able to meet the speed and volume demands necessary for rapid vaccine production during health emergencies (1, 2). Advancements in drug delivery systems play a crucial role in enhancing vaccine efficacy, stability, and immunogenicity. Traditional delivery methods, such as intramuscular and subcutaneous injections, often face challenges related to antigen degradation and limited immune response. AI-driven innovations have enabled the optimization of novel delivery platforms, including lipid nanoparticles, virus-like particles, and micro needle patches, improving bioavailability and controlled release. AI models assist in predicting nanoparticle interactions, refining formulation designs, and ensuring targeted immune activation. Additionally, AI facilitates personalized vaccine delivery by analyzing genetic and immunological data, optimizing dosages, and enhancing patient-specific immune responses. These advancements are particularly transformative for mRNA vaccines, which rely on lipid nanoparticle carriers for efficient intracellular delivery, improving vaccine potency and stability (2).

1.2. Evidence Acquisition: The Emergence of Artificial Intelligence in Healthcare

Artificial Intelligence (AI) encompasses various computational approaches, including machine learning (ML), deep learning (DL), natural language processing (NLP), and computer vision (3). These technologies excel in their ability to learn from data, recognize patterns, and make decisions without direct human intervention. AI has had a transformative impact on healthcare, with applications spanning diagnostics, personalized medicine, drug development, and clinical trial optimization (4). In the context of vaccine development, AI's capacity to analyze vast amounts of biological data significantly accelerates the identification of potential vaccine candidates. In the post-genomic era, high-throughput sequencing methods produce large datasets, which AI systems can process to predict vaccine efficacy by evaluating epidemiological, genomic, and proteomic data (5). Furthermore, AI can optimize vaccine distribution logistics, streamline manufacturing processes, and enhance clinical trial design, ultimately making vaccine development more efficient and responsive to global health needs (6).

This study aims to explore how AI is transforming vaccine research, development, and production, particularly in enhancing accessibility, efficacy, and efficiency in response to emerging infectious diseases.

2. Artificial Intelligence in Vaccine Research

2.1. Role of AI in Identifying Vaccine Targets

The identification of antigens—molecular structures that elicit an immune response—is a crucial initial step in the creation of vaccines. In the past, this has required arduous laboratory effort, protein isolation from bacteria or viruses, and testing in animal models (7). Yet AI has transformed this procedure by employing sophisticated algorithms to find potential vaccination targets by sorting through enormous biological datasets (8). Artificial intelligence methods, including supervised learning and unsupervised learning models, have demonstrated potential in the analysis of protein structures, identification of pathogen areas with high conservation, and prediction of antigenic epitopes (9). To identify the epitopes most likely to trigger protective immunity, for example, ML models such as Random Forest and Support Vector Machines (SVMs) may effectively analyse the sequencing data of a virus, such SARS-CoV-2 (Table 1) (10).

Table 1: Overview of AI Algorithms for Identifying Vaccine Targets

Algorithm	**Application**	**Key findings**
Random Forest	Protein structure prediction	Enhanced accuracy in identifying potential vaccine targets
Support Vector Machine	Antigen epitope mapping	Improved identification of immunogenic epitopes
Convolutional Neural Networks (CNNs)	Structural bioinformatics	Accurate prediction of protein structures
Long Short-Term Memory (LSTM) Networks	Predicting immune response	Effective prediction of long-term immune responses
Hidden Markov Models	Sequence analysis	Better prediction of conserved regions in pathogen genomes

The capacity of AI to simulate interactions between proteins is an additional significant benefit. Convolutional neural networks (CNNs) and recurrent neural networks (RNNs) in particular are examples of deep learning models that have proven to be effective in comprehending how viral proteins interact with human immune cells and in predicting the three-dimensional structure of proteins. AI can assist in prioritising antigens for vaccine development by mapping these interactions (11,12).

2.2. Data Mining and Predictive Analytics in Vaccine Discovery

The technique of collecting meaningful information from massive databases is known as "data mining," and it has become an essential tool in the field of vaccine development (13). Large libraries of genetic and epidemiological data are housed in public databases including GenBank, the Protein Data Bank (PDB), and the Global Initiative on Sharing Avian Influenza Data (GISAID) (14). These datasets may be quickly analysed by AI-driven data mining tools to find trends that may guide the creation of vaccines. As AI models may find trends in mutations, transmission, and severity by examining past viral epidemics of influenza, Ebola, and coronaviruses. These discoveries allow scientists to predict the features of upcoming virus strains and to predict future outbreaks. As demonstrated by coronaviruses like SARS and MERS, predictive analytics driven by AI can assist in identifying possible zoonotic spill over occurrences, allowing for proactive vaccine development (15,16).

Additionally, by forecasting vaccine candidates' efficacy using past vaccination performance data, AI may rank vaccine candidates in order of preference. Researchers can save a significant amount of time and money at the preclinical stage by using predictive models based on historical data from vaccine trials to determine which antigens are most likely to elicit a high immune response (17).

2.3. Machine Learning for Antigen Prediction

AI has demonstrated a pivotal role in enhancing the precision of antigen prediction, which is a crucial aspect of vaccine design. Peptide sequence analysis and antigenicity prediction have been performed using machine learning models, namely CNNs and LSTMs. This is accomplished by letting the models understand which sequence patterns are linked to potent immune responses by training them on big datasets of known epitopes (18).

Using AI to forecast the antigenicity of SARS-CoV-2 spike protein epitopes during the COVID-19 vaccine development process is one well-known example (10). The fast creation of mRNA vaccines like those made by Pfizer-BioNTech and Moderna was made possible by AI models' ability to identify epitopes that were most likely to elicit neutralising antibodies (19).

The capacity of AI to account for genetic diversity within pathogens is another benefit of utilising AI for antigen prediction. This is especially crucial for quickly evolving viruses, such as HIV and influenza, where antigenic drift and shift can make vaccinations useless. In order to create vaccinations that offer wider protection, AI algorithms may be taught to forecast which virus variations are most likely to develop (20).

3. AI in Vaccine Development

3.1. Accelerating Preclinical Trials with AI

One major roadblock in the production of vaccines is preclinical testing, which entails research in laboratories and on animals. It may be time-consuming and expensive to assess vaccination candidates for safety and effectiveness using conventional methods. But by offering instruments to mimic biological systems and forecast the results of treatments prior to in vivo testing, AI has the potential to revolutionise preclinical research (21).

Through the use of AI-driven computer models, such as in silico trials, researchers may prioritise the most promising vaccination candidates for additional testing by simulating the immune system's reaction to various formulations. These models can forecast a vaccine's preclinical study outcomes by taking into consideration factors like adjuvant combinations, antigen dose, and administration route (intramuscular vs. subcutaneous, for example) (22). The creation of new antigens using generative models is a potential use of AI in preclinical research. Virtual antigen candidates that are optimised for immunogenicity can be produced by researchers through the use of techniques such as Generative Adversarial Networks (GANs). As a result, less trial-and-error testing in the lab is required, hastening the creation of vaccines (23).

3.2. AI-Driven Design of Vaccine Formulations

The process of formulating vaccines is intricate and entails choosing an adjuvant and delivery mechanism in addition to the antigen that will stimulate the most potent and long-lasting immune response (24). This procedure has historically relied heavily on in-depth in vitro and in vivo testing and has been mostly empirical. But by facilitating a more logical design approach, AI is revolutionising vaccine development (25). AI can anticipate which combinations of antigens and adjuvants will most effectively elicit the intended immune response by modelling their molecular interactions using molecular docking simulations (26). This has been very helpful in the creation of vaccines using nanoparticles, which employ carefully designed particles to transfer antigens to immune cells. AI is also essential for maximising the stability of vaccines. AI models are able to forecast which formulations will maintain their stability throughout storage and transportation by examining the molecular structures of adjuvants, stabilisers, and antigens. This is especially crucial for vaccines that depend on cold-chain logistics to be effective, such as the mRNA-based COVID-19 vaccines (27,28).

3.3. Simulation Models for Clinical Trial Outcomes

One of the most costly and time-consuming stages of vaccine research is clinical trials, which can take several years to finish (29). But by modelling trial results before they are carried out, AI can assist in lowering the length and expense of clinical trials (30). Based on variables including age, gender, genetic background, and health status, these simulations employ sophisticated modelling approaches to forecast how various populations will react to a vaccination.

Adaptive trial design is one of the main uses of AI in clinical trial design (30). Conventional clinical trials have a predetermined trial design from the start, which may result in inefficiencies if the vaccine's performance isn't as expected at first. On the other hand, researchers may adjust the trial design using AI-powered adaptive trials when fresh data becomes available, which maximises resource allocation and lowers the risk of failure. AI may also be used to forecast the ideal dose for any demographic subgroup and simulate various dosing schedules. This is especially crucial when it comes to vaccinations, as a person's age, health, and history of infection may all have a big impact on their immune response (31).

4. AI in Vaccine Production

4.1. Optimization of Manufacturing Processes

Vaccines are produced on a huge scale using complex procedures that call for accuracy, effectiveness, and adaptability—especially in times of pandemic or other emergency involving public health. Thanks to its ability to analyse and find patterns in vast datasets created by manufacturing operations, AI has become a transformational tool for optimising these processes and streamlining production. Artificial Intelligence has the potential to maximise yield by optimising bioreactor settings, such as ensuring that cells making antigen proteins develop under ideal circumstances (32). Machine learning algorithms are able to anticipate the effects of various circumstances on antigen production by analysing variables including pH, temperature, and nutrition levels. AI can drastically save the time and expense of producing vaccines by determining the most effective production conditions. AI also aids in the optimisation of process scale-up from the laboratory to industrial levels, a crucial stage in the manufacture of vaccines. Large-scale manufacturing typically finds it difficult to reproduce the small-scale laboratory success using conventional methods (33). But AI can simulate various situations and forecast the most effective ways to scale up, guaranteeing that the procedure stays economical and efficient even when manufacturing millions of doses (5).

4.2. Quality Control and Assurance through AI

To guarantee vaccines' safety and effectiveness, quality control must be maintained throughout the manufacturing process. AI technologies are being used more often in quality control to track and evaluate the production process in real-time, lowering the possibility of human mistake and guaranteeing a constant level of product quality.

Anomaly detection models, which are machine learning techniques, are employed to detect variations in production data that may signify problems with quality (34). Such anomalous patterns as variations in antigen concentration, contamination, or temperature swings during storage can be identified by these models and may otherwise go undetected. Early detection of these abnormalities by AI enables prompt remedial action, eliminating possible quality failures that may jeopardise the safety or effectiveness of vaccines.

By employing predictive analytics to foresee possible quality problems based on past data, AI also increases the accuracy of quality assurance. Manufacturers can take preventative measures to ensure product quality, for example, by analysing data gathered from prior vaccination batches to forecast future quality trends (Table 2) (35).

Table 2: Applications of AI in Vaccine Quality Control and Assurance

Application	Description	Impact on Vaccine Production
Anomaly Detection	Identifying deviations in production data	Early identification of potential quality issues
Predictive Analytics	Forecasting quality trends	Improved quality assurance and compliance
Reinforcement Learning	Adaptive quality control	Continuous optimization of quality monitoring systems

4.3. Supply Chain Management and Distribution

In the event of a global health emergency, in particular, prompt delivery of vaccinations to the intended populations depends on effective supply chain management. Demand forecasting, inventory management, and logistics optimisation may all be significantly improved using AI-driven supply chain management systems. Accurately forecasting demand is one of the most important distribution issues for vaccines. Artificial intelligence algorithms have the capacity to examine several variables, including disease transmission trends, demographics of the population, and past vaccination records, in order to more accurately predict demand. As a result, producers and public health groups can modify their production plans to ensure that there are enough vaccine doses to fulfil demand (36). Furthermore, vaccination distribution may be optimised by AI-powered logistics systems, guaranteeing that doses are given to the appropriate places at the appropriate times (37). AI can identify the most effective ways to deliver vaccines, minimising delays and saving waste, by analysing data on transportation routes, storage capacity, and cold chain needs (37,38). This is particularly crucial for vaccinations that need to be maintained at extremely low temperatures and have strict cold chain requirements, as the COVID-19 mRNA vaccine (37,38). AI may also be used to better efficiently manage the stock of vaccines. Health officials may restock vaccination supplies ahead of time by using predictive algorithms to predict when and where vaccine supplies will run low. AI may also be used to track the expiry dates of vaccines (37,38).

5. AI in Vaccine Development against Multidrug-Resistant Bacteria

Several investigations have utilised AI-driven approaches, as presented in table 3, to investigate the creation of vaccinations that specifically target microorganisms that are resistant to several drugs. For example, an *in-silico* investigation employing AI approaches revealed 22 membrane proteins as putative antigens within the Helicobacter pylori proteome. Similarly, AI techniques were used in *Acinetobacter baumannii* research to suggest and experimentally confirm FilF, an outer membrane protein thought to serve as a pilus assembly protein, as a potential vaccine candidate. Another study using 33 *A. baumannii* genomes found that AI-driven reverse vaccinology (RV) techniques might effectively find vaccine candidates that would guard against strains of the infection that are resistant to antibiotics. Furthermore, T-cell epitopes in a variety of Mycobacterium species have been identified and characterised using computational techniques. Interestingly, the application of immunoinformatic to Mycobacterium tuberculosis (Mtb) using a number of AI-based methods has resulted in the discovery of immunogenic epitopes that may be included in candidate vaccines for further in vitro testing (39-43).

Table 3: Key AI techniques and methodologies for identifying potential vaccine candidates

Study	**Bacteria/Pathogen**	**AI Method Used**	**Vaccine Candidates Identified**	**Key findings**
(39)	*Helicobacter pylori*	In silico analysis	22 membrane proteins as potential antigens	Identified novel antigens for vaccine development.
(40)	*Acinetobacter baumannii*	AI-driven methods	FilF outer membrane protein	Validated as a promising vaccine candidate.
(41)	*Acinetobacter baumannii*	Reverse vaccinology	Various candidates for antibiotic-resistant strains	Enhanced protection strategies against infections.
(42)	*Mycobacterium tuberculosis*	Immunoinformatics	Immunogenic epitopes	Potential for inclusion in candidate vaccines.
(43)	*Mycobacterium spp.*	Computational identification	Multiple T-cell epitopes	Aided in understanding immune response mechanisms.

5.1. The Role of AI in Overcoming Antimicrobial Resistance

The development of new drugs and vaccines is required due to the growth of antimicrobial resistance. When it comes to vaccine research, AI-assisted computational methodologies offer a competitive alternative to conventional empirical methods. The COVID-19 pandemic demonstrated the effectiveness of these AI techniques, which improved diagnostic skills and allowed for the quick discovery and validation of new vaccine candidates (44).

AI systems are skilled at recognising microbial components with low mutation rates, which guarantees the long-term effectiveness of vaccines. AI has the capability to monitor genetic alterations over time and optimise vaccination formulations by combining data from many experimental and real-world sources. Modern AI algorithms have made it possible to include reverse vaccinology approaches, which have revolutionised the discovery of prospective antigens and greatly streamlined the vaccine production process (44).

6. Challenges and Limitations

6.1. Ethical Considerations in AI Applications

Although AI has many advantages for vaccine development, production, and research, it also poses serious ethical concerns. A significant issue is the possibility of bias in AI algorithms, especially in the context of vaccination candidate selection and clinical trial result prediction (45). AI-driven vaccine development faces ethical challenges, particularly around data privacy, as sensitive health information is often required for training AI models. Ensuring secure data handling and adherence to privacy regulations like GDPR and HIPAA is essential (45). AI algorithms may reinforce current healthcare disparities by giving vaccinations priority to communities who are already well-represented in the data if they are trained on skewed or incomplete data (46). For instance, a machine learning model used to design clinical trials may not take into consideration the unique needs of individuals in low-income areas if it was trained largely on data from clinical trials carried out in high-income nations. Algorithmic bias remains a significant concern. AI models trained on non-diverse datasets may produce skewed results, affecting vaccine efficacy and safety across different populations. To mitigate this, researchers should prioritize diverse and inclusive datasets and actively address biases in the models. As a result, immunisations may become less effective or more difficult for underprivileged groups to get. Transparency is critical in AI decision-making. The black-box nature of deep learning models makes it difficult to understand how decisions are made, which can reduce trust in AI applications in vaccine development. Improved explainability of AI models is crucial to build confidence and ensure accountability. The key to reducing this risk is making sure AI models are trained on a variety of representative datasets.

Concerns about data privacy are another ethical issue. AI models used in vaccination research frequently need access to enormous volumes of sensitive data, such as demographic, medical, and genetic data. It is crucial to make sure that this data is handled appropriately and is secured. Data breaches have the potential to jeopardise patient privacy and reduce public confidence in attempts to produce vaccines (47). Establishing strong rules for the use of AI in vaccine development is crucial in order to overcome these ethical problems. According to Blanco-González et al. (47), these rules should place a high priority on openness, accountability, and justice in order to guarantee that AI is applied in a way that benefits all groups equally.

6.2. Data Privacy and Security Concerns

The application of AI in vaccine development necessitates having access to sizable datasets, such as genetic data, clinical trial data, and patient health records (48). Al-Khassawneh et al. (49) note that although this data is helpful for training AI models, it also creates serious privacy and security problems. The healthcare industry frequently experiences data breaches, which can have serious repercussions. Sensitive patient information that is lost or stolen may result in identity theft, prejudice, or other negative outcomes (46). Furthermore, a well-publicized data leak has the potential to erode public confidence in the institutions responsible for developing vaccines, hence impeding vaccination rates (48).

Organisations must put strict security measures in place to safeguard the data they gather in order to reduce these dangers. To protect sensitive information, this involves utilising technology like encryption, access restrictions, and others. Moreover, businesses should take a data-minimization strategy, gathering just the information required to train AI models and making sure that data is anonymised whenever feasible (49). In addition to technological controls, legislative frameworks that govern AI applications in healthcare and guarantee patients' rights are crucial (50). Many nations have privacy laws that provide guidelines for data protection, such as the Health Insurance Portability and Accountability Act (HIPAA) in the US and the General Data Protection Regulation (GDPR) in the EU; however, as AI technologies advance, more laws might be required (50).

7. Future Directions

7.1. Advancements in AI Technologies

The use of AI technologies in vaccine development is expected to grow as they develop further. Quantum computing is one of the most fascinating fields of AI research because it has the potential to completely change how data is processed. Quantum computers may process several states at once, which enables them to do complicated computations at previously unheard-of rates, in contrast to conventional computers, which process information in binary (0s and 1s). Quantum computing has the potential to significantly speed up the process of finding potential vaccine candidates by enabling researchers to analyse large datasets faster than they can now. Looking toward the future, quantum computing holds the potential to process larger datasets, making AI models more efficient in vaccine research. Additionally, AI could play a key role in the development of personalized vaccines, creating tailored vaccines based on individual genetic profiles. To better understand how vaccines function and might be improved, quantum algorithms, for instance, could be used to model the atomic-level interactions between viral proteins and the immune system.

Apart from quantum computing, the prediction accuracy of AI models utilised in vaccine research is anticipated to increase due to developments in AI algorithms. For instance, the creation of more complex deep learning models, like transformers, may improve AI's capacity to forecast antigenicity and improve vaccine compositions. These developments will be especially crucial for creating vaccines against complicated infections like HIV, where more conventional methods have failed.

The integration of AI with other cutting-edge technologies, such synthetic biology and CRISPR, is another exciting field of study. Through the integration of AI's predictive powers with the accuracy of gene-editing instruments, scientists might potentially create totally new vaccination classes that are both more efficient and simpler to manufacture.

8. Conclusion

8.1. Summary of Key Findings

Artificial intelligence (AI) is significantly transforming vaccine research, development, and manufacturing. By enabling faster identification of vaccine targets, optimizing antigenicity predictions, improving manufacturing processes, and ensuring quality control, AI accelerates vaccine development. The use of machine learning, deep learning, and natural language processing allows researchers to analyze large datasets, predict clinical outcomes, and optimize formulations more efficiently. These advancements are particularly crucial in responding to emerging infectious diseases, where rapid vaccine development is vital. However, challenges such as the need for multidisciplinary collaboration and ethical concerns related to bias and data privacy must be addressed to ensure AI's fair and ethical use in vaccine development.

8.2. The Future of AI in Vaccine Development

As AI technologies advance, their impact on vaccine development will continue to grow. Quantum computing, improved AI algorithms, and collaboration with other technologies could revolutionize vaccine creation, particularly for complex diseases. AI also has the potential to enhance global vaccine equity by optimizing supply chains, reducing costs, and ensuring more equitable distribution. Future innovations will stem from closer collaboration between AI experts and vaccine researchers, leading to faster, more effective responses to emerging infectious diseases and global health crises.

Acknowledgment: The authors would like to thank all authors included in this systematic review.

Author Contributions: M.Y.N and B.S. Conceptualization, Data curation, Formal analysis, Investigation.

K.G.D. and M.S. Data curation, Writing – review & editing.

Z.S. Supervisor, Writing – original draft.

Data Availability: The data supporting the findings of this study are available upon reasonable request from the corresponding author.

Funding: There is no any funding for this work.

Conflicts of Interest: The authors declare no conflict of interests.

Ethical Statement: This review article adheres to ethical guidelines for scholarly writing. All sources and references used in the preparation of this manuscript have been properly cited to give credit to the original authors

References

1. Ankomah AA, Moa A, Chughtai AA. The long road of pandemic vaccine development to rollout: a systematic review on the lessons learnt from the 2009 H1N1 influenza pandemic. American Journal of Infection Control. 2022;50(7):735-742. https://doi.org/10.1016/j.ajic.2022.01.026
2. Iqbal, S., Omara, T., Kahwa, I., & Khan, U. M. (2024). Anticancer potential of delphinidin and its derivatives: therapeutic and mechanistic insights. Medicinal Chemistry Research, 33(10), 1769-1786.
3. Soori M, Arezoo B, Dastres R. Artificial intelligence, machine learning and deep learning in advanced robotics: a review. Cognitive Robotics. 2023; 3:54-70.
4. Johnson KB, Wei WQ, Weeraratne D, Frisse ME, Misulis K, Rhee K, et al. Precision medicine, AI, and the future of personalized health care. Clinical and Translational Science. 2021;14(1):86-93.
5. Vora LK, Gholap AD, Jetha K, Thakur RRS, Solanki HK, Chavda VP. Artificial intelligence in pharmaceutical technology and drug delivery design. Pharmaceutics. 2023;15(7):1916. https://doi.org/10.3390/pharmaceutics15071916
6. Olawade DB, Teke J, Fapohunda O, Weerasinghe K, Usman SO, Ige AO, David-Olawade AC. Leveraging artificial intelligence in vaccine development: a narrative review. Journal of Microbiological Methods. 2024;106998.
7. Zhuang Z, Zhuo J, Yuan Y, Chen Z, Zhang S, Zhu A, et al. Harnessing T-cells for enhanced vaccine development against viral infections. Vaccines. 2024; 12(5):478.
8. Nayarisseri A, Khandelwal R, Tanwar P, Madhavi M, Sharma D, Thakur G, et al. Artificial intelligence, big data and machine learning approaches in precision medicine & drug discovery. Current Drug Targets. 2021;22(6):631-655.
9. Bravi B. Development and use of machine learning algorithms in vaccine target selection. npj Vaccines. 2024;9(1):15.
10. Cihan P, Ozger ZB. A new approach for determining SARS-CoV-2 epitopes using machine learning-based in silico methods. Computational Biology and Chemistry. 2022; 98:107688. https://doi.org/10.1016/j.compbiolchem.2022.107688
11. Lee M. Recent advances in deep learning for protein-protein interaction analysis: a comprehensive review. Molecules. 2023; 28(13):5169.

12. Tran H-N, Nguyen P-X-Q, Guo F, Wang J. Prediction of protein–protein interactions based on integrating deep learning and feature fusion. International Journal of Molecular Sciences. 2024;25(11):5820. https://doi.org/10.3390/ijms25115820
13. Kasten JE. Big data applications in vaccinology. International Journal of Big Data and Analytics in Healthcare. 2021;6(2):59-80.
14. Vello F, Filippini F, Righetto I. Bioinformatics goes viral: I. Databases, phylogenetics and phylodynamics tools for boosting virus research. Viruses. 2024;16(9):1425.
15. Stockdale JE, Liu P, Colijn C. The potential of genomics for infectious disease forecasting. Nature Microbiology. 2022;7(11):1736-1743.
16. Das D, Biswas SK, Bandyopadhyay S. Perspective of AI system for COVID-19 detection using chest images: a review. Multimedia Tools and Applications. 2022;81(15):21471-21501.
17. Sharma A, Virmani T, Pathak V, Sharma A, Pathak K, Kumar G, Pathak D. Artificial intelligence-based data-driven strategy to accelerate research, development, and clinical trials of COVID vaccine. Biomedical Research International. 2022;2022:7205241. https://doi.org/10.1155/2022/7205241
18. Ozsahin DU, Ameen ZS, Hassan AS, Mubarak AS. Enhancing explainable SARS-CoV-2 vaccine development leveraging bee colony optimised Bi-LSTM, Bi-GRU models and bioinformatic analysis. Scientific Reports. 2024;14(1):6737. https://doi.org/10.1038/s41598-024-55762-7
19. Narowski TM, Raphel K, Adams LE, Huang J, Vielot NA, Jadi R, de Silva AM, Baric RS, Lafleur JE, Premkumar L. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people. Cell Reports.2022;38(5):110336. https://doi.org/10.1016/j.celrep.2022.110336
20. Malik S, Asghar M, Waheed Y. Outlining recent updates on influenza therapeutics and vaccines: a comprehensive review. Vaccine: X. 2024;100452.
21. Baldwin J, Piplani S, Sakala IG, Honda-Okubo Y, Li L, Petrovsky N. Rapid development of analytical methods for evaluating pandemic vaccines: a COVID-19 perspective. Bioanalysis. 2021;13(24):1805-1826. https://doi.org/10.4155/bio-2021-0096
22. Fan J, Jin S, Gilmartin L, Toth I, Hussein WM, Stephenson RJ. Advances in infectious disease vaccine adjuvants. Vaccines. 2022;10(7):1120.

23. Hayawi K, Shahriar S, Alashwal H, Serhani MA. Generative AI and large language models: a new frontier in reverse vaccinology. Informatics in Medicine Unlocked. 2024;101533.
24. D'Amico C, Fontana F, Cheng R, Santos HA. Development of vaccine formulations: past, present, and future. Drug Delivery and Translational Research. 2021; 11:353-372.
25. Selvaraj C, Chandra I, Singh SK. Artificial intelligence and machine learning approaches for drug design: challenges and opportunities for the pharmaceutical industries. Molecular Diversity. 2021;1-21.
26. Zhang WY, Zheng XL, Coghi PS, Chen JH, Dong BJ, Fan XX. Revolutionizing adjuvant development: harnessing AI for next-generation cancer vaccines. Frontiers in Immunology. 2024; 15:1438030.
27. Oude Blenke E, Örnskov E, Schöneich C, Nilsson GA, Volkin DB, Mastrobattista E, Almarsson Ö, Crommelin DJA. The storage and in-use stability of mRNA vaccines and therapeutics: not a cold case. Journal of Pharmaceutical Sciences. 2023;112(2):386-403. https://doi.org/10.1016/j.xphs.2022.11.001
28. Schoenmaker L, Witzigmann D, Kulkarni JA, Verbeke R, Kersten G, Jiskoot W, Crommelin DJ. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. International Journal of Pharmaceutics. 2021; 601:120586.
29. Singh B, Maurya DK, Kumar R, Chauhan SB, Mudavath SL, Meena RN, et al. Vaccine human clinical trial. In: System Vaccinology. Academic Press; 2022. p. 281-296.
30. Askin S, Burkhalter D, Calado G, El Dakrouni S. Artificial intelligence applied to clinical trials: opportunities and challenges. Health and Technology. 2023;13(2):203-213.
31. Suriyaamporn P, Pamornpathomkul B, Patrojanasophon P, Ngawhirunpat T, Rojanarata T, Opanasopit P. The artificial intelligence-powered new era in pharmaceutical research and development: a review. AAPS PharmSciTech. 2024;25(6):188.
32. Randhawa JS, Rao R, Tiwari K, Meehnian H, Kumar S. Online monitoring tools for vaccine production in bioreactors. In: Bioreactor Design Concepts for Viral Vaccine Production. Academic Press; 2024. p. 401-416.

33. Kapustina O, Burmakina P, Gubina N, Serov N, Vinogradov V. User-friendly and industry-integrated AI for medicinal chemists and pharmaceuticals. Artificial Intelligence Chemistry. 2024;100072.
34. Jaramillo-Alcazar A, Govea J, Villegas-Ch W. Anomaly detection in a smart industrial machinery plant using IoT and machine learning. Sensors. 2023;23(19):8286.
35. Alowais SA, Alghamdi SS, Alsuhebany N, Alqahtani T, Alshaya AI, Almohareb SN, et al. Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC Medical Education. 2023;23(1):689. https://doi.org/10.1186/s12909-023-04698-z
36. Badidi E. Edge AI for early detection of chronic diseases and the spread of infectious diseases: opportunities, challenges, and future directions. Future Internet. 2023;15(11):370.
37. Hu H, Xu J, Liu M, Lim MK. Vaccine supply chain management: an intelligent system utilizing blockchain, IoT, and machine learning. Journal of Business Research. 2023; 156:113480. https://doi.org/10.1016/j.jbusres.2022.113480
38. Selamoglu M. The importance of the cold chain logistics in the pandemic: the transport of COVID-19 vaccines. Op Acc J Bio Sci & Res. 2021;10(1).
39. Rahman, N., Ajmal, A., Ali, F., & Rastrelli, L. (2020). Core proteome mediated therapeutic target mining and multi-epitope vaccine design for Helicobacter pylori. Genomics, 112(5), 3473–3483. https://doi.org/10.1016/j.ygeno.2020.06.026
40. Singh, R., Garg, N., Shukla, G., Capalash, N., & Sharma, P. (2016). Immunoprotective efficacy of Acinetobacter baumannii outer membrane protein, FilF, predicted in silico as a potential vaccine candidate. Frontiers in Microbiology, 7. https://doi.org/10.3389/fmicb.2016.00158
41. Chiang, M. H., Sung, W. C., Lien, S. P., Chen, Y. Z., Lo, A. F., Huang, J. H., et al. (2015). Identification of novel vaccine candidates against Acinetobacter baumannii using reverse vaccinology. Human Vaccines & Immunotherapeutics, 11(4), 1065–1073. https://doi.org/10.1080/21645515.2015.1010910
42. Hossain, M. S., Azad, A. K., Chowdhury, P. A., & Wakayama, M. (2017). Computational identification and characterization of a promiscuous T-cell epitope on the extracellular protein 85B of Mycobacterium spp. for peptide-based subunit vaccine design. BioMed Research International, 2017, 4826030. https://doi.org/10.1155/2017/4826030

43. Panigada, M., Sturniolo, T., Besozzi, G., Boccieri, M. G., Sinigaglia, F., Grassi, G. G., et al. (2002). Identification of a promiscuous T-cell epitope in Mycobacterium tuberculosis Mce proteins. Infection and Immunity, 70(1), 79–85.https://doi.org/10.1128/IAI.70.1.79-85.2002
44. Thomas S, Abraham A, Baldwin J, Piplani S, Petrovsky N. Artificial intelligence in vaccine and drug design. In: Methods in Molecular Biology. Vol. 2410; 2022. p. 131–146. https://doi.org/10.1007/978-1-0716-1884-4_6
45. Agarwal R, Bjarnadottir M, Rhue L, Dugas M, Crowley K, Clark J, Gao G. Addressing algorithmic bias and the perpetuation of health inequities: an AI bias aware framework. Health Policy and Technology. 2023;12(1):100702.
46. Abbasi N, Nizamullah FNU, Zeb S. AI in healthcare: using cutting-edge technologies to revolutionize vaccine development and distribution. Jurihum: Jurnal Inovasi dan Humaniora. 2023;1(1):17-29.
47. Blanco-González A, Cabezón A, Seco-González A, Conde-Torres D, Antelo-Riveiro P, Piñeiro Á, Garcia-Fandino R. The role of AI in drug discovery: challenges, opportunities, and strategies. Pharmaceuticals. 2023;16(6):891. https://doi.org/10.3390/ph16060891
48. Mennella C, Maniscalco U, De Pietro G, Esposito M. Ethical and regulatory challenges of AI technologies in healthcare: a narrative review. Heliyon. 2024.
49. Al-Khassawneh YA. A review of artificial intelligence in security and privacy: research advances, applications, opportunities, and challenges. Indonesian Journal of Science and Technology. 2023;8(1):79-96.
50. Schmidt J, Schutte NM, Buttigieg S, Novillo-Ortiz D, Sutherland E, Anderson M. Mapping the regulatory landscape for artificial intelligence in health within the European Union. npj Digital Medicine. 2024;7(1):229.